Search results
Results from the WOW.Com Content Network
With full FDA approval for the groundbreaking Alzheimer’s drug Leqembi, Medicare coverage takes a big step forward into a new era of treatment.
In early 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval to a new Alzheimer’s drug called Leqembi. (Biogen, a biotechnology company, and Eisai, a pharmaceutical ...
The change, which CMS Administrator Chiquita Brooks-LaSure announced in a news release, is a win for advocacy groups, including the Alzheimer's Association, that have been seeking broader access ...
The Sunshine Act requires manufacturers of drugs, medical devices, biological and medical supplies covered by the three federal health care programs Medicare, Medicaid, and State Children's Health Insurance Program (SCHIP) to collect and track all financial relationships with physicians and teaching hospitals and to report these data to the Centers for Medicare and Medicaid Services (CMS).
Leqembi, which won full U.S. regulatory approval last month, is the first treatment proven to slow progression of the mind-robbing disease for people in the earliest stages of Alzheimer's.
CHICAGO (Reuters) -The U.S. Medicare health plan on Thursday offered details of plans to collect patient data as a condition for reimbursement for Eisai Co Ltd and Biogen Inc's new Alzheimer's ...
The Food and Drug Administration’s decision this week to approve a new Alzheimer’s drug for the first time in nearly 20 years was highly anticipated — and highly questioned. It’s also ...
Because it is a disease of aging, most Alzheimer's patients are covered by Medicare, which had effectively denied coverage of Leqembi under the accelerated approval it received in January. The ...